AbbVie and Principia Announce Collaboration on Oral Immunoproteasome Inhibitors

AbbVie and Principia Announce Collaboration on Oral Immunoproteasome Inhibitors

The collaboration is aimed at developing first-in-class oral therapies that bring the power of proteasome inhibition safely into the field of immunology. 

Atreca and Dana-Farber to partner on cancer immunotherapy

Atreca and Dana-Farber to partner on cancer immunotherapy

Atreca will apply its Immune Repertoire Capture® technology to generate sequences of native antibodies and TCRs from patients.

Caribou's Rachel Haurwitz speaks at TechCrunch NYC

Caribou's Rachel Haurwitz speaks at TechCrunch NYC

The Caribou CEO and co-founder spoke at TechCrunch Disrupt about the ethical and legal challenges of CRISPR technology.

Bioverativ to buy True North Therapeutics for $400M

Bioverativ to buy True North Therapeutics for $400M

True North is a Mission Bay Capital portfolio company pursuing therapies that target the complement system to treat rare diseases.

Symic Bio Secures $30 Million Series B Financing

Symic Bio Secures $30 Million Series B Financing

Symic recently graduated from the QB3@953 incubator after several years' residence.

Vinod Khosla leads $24.5M Series A for Two Pore Guys

Vinod Khosla leads $24.5M Series A for Two Pore Guys

Two Pore Guys was spun out of research at UC Santa Cruz by William Dunbar and Trevor Morin. Their core technology is a handheld molecular sensor based on solid-state nanopores.

Circle Pharma expands its Series A funding

Circle Pharma expands its Series A funding

Circle was founded as a collaboration between Matt Jacobson at UCSF and Scott Lokey at UC Santa Cruz. The company is designing macrocyclic peptide therapeutics.

Celgene acquires autoimmune startup Delinia for $300M+

Celgene acquires autoimmune startup Delinia for $300M+

Celgene bought the startup for $300 million upfront to expand its inflammation and immunology pipeline with Delinia's regulatory T cell therapy.

Novartis invests in, partners with Perlara

Novartis invests in, partners with Perlara

Novartis invested and partnered with Perlara, a resident of QB3@953, to discover and develop treatments for lysosomal storage disorders using CRISPR-engineered animal models.

Meet Trace Genomics, The "23andMe" Of Soil

Meet Trace Genomics, The "23andMe" Of Soil

For $199, farmers can understand their soil better—which is key to keeping their crops healthy.